Leading Justice is a full-service marketing company working with law firms on a cash-buy basis to sign up fully qualified, fraud-free pentosan polysulfate-related maculopathy cases. Here at Leading Justice, we can customize your firm’s Elmiron advertising needs and help you sign up cases via internal cash buys. Our clients only pay an agency fee to cover the cost of Elmiron maculopathy advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that doesn’t qualify for the target campaign is evaluated to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to Elmiron and side effects like pigmentary maculopathy, eye damage, vision loss and blindness, Leading Justice will increase your firm’s Elmiron caseload. If you are interested in helping victims of Elmiron side effects, our direct advertising strategies and extensive consumer reach at Leading Justice give you the competitive edge and confidence you need to allocate your full budget, knowing that your money is being spent in the best way possible.
Each law firm we work with at Leading Justice plays an important role in determining how we categorize claims as qualified or not. And while our experience working with plaintiff law firms allows us to recognize a great case when we see one, we will tailor our Elmiron vision loss intake specifications to the exact criteria you are seeking. So, if your firm has specific Elmiron qualifying case criteria you want us to use, we can train our intake specialists to apply the criteria to each phone call and email they receive. By eliminating the middle man, Leading Justice offers clients an opportunity for internal cash buys of Elmiron maculopathy data with zero chance of fraud.
Elmiron Maculopathy Litigation
Since 1996, the bladder drug Elmiron (pentosan polysulfate or PPS) has been marketed in the United States as a safe and effective treatment for interstitial cystitis (IC), a chronic condition that is part of a spectrum of diseases known collectively as painful bladder syndrome. Many of these patients experienced symptoms like vision loss, blurred vision, difficulty reading and vision distortion during or after Elmiron treatment and were diagnosed with macular degeneration, Stargardt disease or another eye disease, only to find out now that their irreversible vision problems may have been caused by Elmiron. Because Elmiron is currently the only FDA-approved oral medication for interstitial cystitis, most IC patients take Elmiron for years, if not decades. And because the vision problems linked to Elmiron are commonly misdiagnosed as macular degeneration, patients suffering from pentosan polysulfate-related maculopathy may continue taking Elmiron, unaware that the drug may be what is causing their problems.
The first warnings about the potential link between Elmiron and a unique form of progressive eye disease, typically diagnosed by ophthalmologists as age-related macular degeneration, pattern dystrophy or Stargardt disease, came in May 2018. In a study published in the journal Ophthalmology, researchers from the Emory Eye Institute in Atlanta, Georgia highlighted six patients experiencing a “unique pigmentary maculopathy,” which the researchers linked to “chronic exposure to pentosan polysulfate sodium (PPS).” There are now more than a dozen reports and papers detailing cases where interstitial cystitis patients taking Elmiron have experienced retinal maculopathy or pigmentary maculopathy possibly leading to irreversible vision loss and eye dysfunction. For more than 20 years, Elmiron has been used by hundreds of thousands of patients with interstitial cystitis or painful bladder syndrome, and many of these patients are now pursuing legal claims against drug maker Janssen Pharmaceuticals. The Elmiron lawsuits accuse the company of failing to properly research the long-term health effects of Elmiron and failing to issue adequate warnings to patients in the United States about the potential for Elmiron to cause permanent vision loss or blindness.